Abstract
Background
Methods
Results
Conclusions
Supplementary Materials
Notes
Ethics Statement
The study plan of this research was reviewed by the Seoul National University College of Medicine/Seoul National University Hospital (IRB NO. H-1802-050-921 and RESEARCH TITLE: Indirect pathological indicators for cardiac sarcoidosis on endomyocardial biopsy or the explant heart for transplantation). Review comments was: Since the risk of research is minimal, it is for expedited review, and the statement of reason for waiver of informed consent is reasonable. According to IRB Approval Criteria, the IRB approves the research. Further details of the rationale for this waiver was that this research was based on retrospective review of medical record and pathology slides, and anonymized case analysis. This analysis did not alter management of patients. See Attachment D: Informed consent and waiver of consent (https://www.hhs.gov/ohrp/sachrp-committee/recommendations/2013-january-10-letter-attachment-d/index.html).
Author contributions
Conceptualization: MJC, JWS, SO. Data curation: MJC, JWS, SO, EAP, SHL, MYK, JYP. Formal analysis: MJC, JWS, SO, EAP, SHL. Funding acquisition: JWS, SO, SHL. Investigation: MJC, JWS, SO, EAP, SHL, MYK, JYP. Methodology: MJC, JWS, SO, EAP, SHL, MYK, JYP. Project administration: JWS, SO. Resources: MJC, JWS, SO, EAP, SHL, MYK, JYP. Super vision: JWS, SO. Visualization: MJC, JWS. Writing—original draft: MJC, JWS. Writing—review & editing: MJC, JWS, SO, EAP, SHL.
References
Table 1.
Case No.a | Sex | Ageb | Extracardiac sarcoidosis | Steroid | Cardiac rhythm | Heart blockc | Ventricular arrhythmiad | LVEF (%) | Heart TPL | MRI diagnosis |
---|---|---|---|---|---|---|---|---|---|---|
Group 1 | ||||||||||
1-1 | M | > 40 | No | No | Sinus | No | No | 22 | Yes | Probable |
1-2 | M | > 40 | No | No | Sinus | No | No | 33 | Yes | Probable |
1-3 | F | > 50 | Not definite | No | Sinus | No | No | 51 | No | Probable |
1-4 | M | > 60 | No | Unknown | Paroxysmal AF | No | No | 30 | No | × |
1-5 | F | > 60 | No | No | Sinus | No | No | 42 | No | Probable |
Group 2 | ||||||||||
2-1 | F | > 70 | No | No | AF | No | No | 15 | No | Probable |
2-2 | F | > 70 | No | No | AF | No | No | 15 | No | Probable |
Group 3 | ||||||||||
3-1 | M | > 50 | No | No | Sinus | Yes | Yes | 44 | No | Probable |
3-2 | F | > 70 | No | Yes | Paroxysmal AF | Yes | No | 40 | No | Possible |
3-3 | M | > 40 | No | No | Sinus | Yes | Yes | 36 | Yes | Nonspecific |
3-4 | F | > 90 | No | Unknown | Sinus | Yes | Yes | 30 | No | Probable |
3-5 | F | > 50 | Yes (lung, lymph node) | Unknown | Sinus | Yes | Yes | 50 | No | × |
3-6 | F | > 70 | No | Yes | Sinus | No | No | 22 | No | Probable |
Group 4 | ||||||||||
4-1 | M | > 60 | No | Unknown | Sinus | No | Yes | 30 | Yes | Probable |
4-2 | M | > 40 | No | No | Sinus | No | No | 33 | Yes | Probable |
4-3 | M | > 70 | No | Unknown | AF | No | No | 56 | No | Nonspecific |
Group 5 | ||||||||||
5-1 | M | > 70 | No | No | Sinus | No | No | 48 | No | Probable |
5-2 | F | > 60 | No | Yes | Sinus | No | No | 35 | No | Nonspecific |
5-3 | F | > 70 | No | Yes | Paroxysmal AF | No | Yes | 35 | No | Nonspecific |
5-4 | M | > 60 | No | No | Sinus | No | No | 48 | No | Nonspecific |
5-5 | M | > 70 | Yes (lymph node) | No | Sinus | No | Yes | 42 | No | Unlikely |
5-6 | F | > 50 | Yes (skin) | Yes | Sinus | Yes | No | 61 | No | Unlikely |
Group 6 | ||||||||||
6-1 | M | > 50 | No | Unknown | Sinus | Yes | Yes | 46 | No | × |
6-2 | M | > 30 | No | No | Sinus | No | No | 30 | No | Nonspecific |
6-3 | M | > 20 | Yes (lymph node) | Yes | Sinus | No | No | 25 | No | Nonspecific |
6-4 | M | > 60 | No | Unknown | Sinus | No | No | 28 | No | Nonspecific |
6-5 | M | > 10 | No | Unknown | Sinus | No | No | 54 | No | Unlikely |
Group 1, endomyocardial biopsies with micro-granuloma as well as histiocytic infiltration, confluent fibrosis and fatty change; Group 2, endomyocardial biopsies with histiocytic infiltration, confluent fibrosis and fatty change but without micro-granuloma; Group 3, endomyocardial biopsies with confluent fibrosis associated with fatty tissue infiltration; Group 4, presence of confluent fibrosis without associated fatty tissue; Group 5, presence of fatty tissue without associated fibrosis; Group 6, none of four possible indicators on endomyocardial biopsy.
LVEF, left ventricular ejection fraction; TPL, transplantation; MRI, magnetic resonance imaging; M, male; F, female; AF, atrail fibrillation.
Table 2.
Our interpretation categoriesa |
MRI finding |
|||||
---|---|---|---|---|---|---|
Probable | Possible | Nonspecific | Unlikely | Not checked | Total | |
1. Positive for cardiac sarcoidosis: presence of four indicators | 4 | - | - | - | 1 | 5 |
2. Probable for cardiac sarcoidosis (1): Presence of three (confluent fibrosis, fatty change and increased histiocytes) but no micro-granuloma | 2 | - | - | - | - | 2 |
3. Probable for cardiac sarcoidosis (2): Presence of confluent fibrosis and fatty tissue infiltration | 3 | 1 | 1 | - | 1 | 6 |
4. Nonspecific (1): Confluent fibrosis without associated fatty tissue | 2 | - | 1 | - | - | 3 |
5. Nonspecific (2): Fatty tissue without associated fibrosis | 1 | - | 3 | 2 | - | 6 |
6. Nonspecific (3): None of four possible indicators on endomyocardial biopsy | - | - | 3 | 1 | 1 | 5 |
Total | 12 | 1 | 8 | 3 | 3 | 27 |
Table 3.
Morphologic patterns | |
---|---|
1. Macroscopic classification of myocardial lesions in cardiac sarcoidosis [25] | |
- Spotty pattern | |
- Conglomerate band-like pattern | |
- Dendritic pattern | |
2. Histologic features of myocardial lesions in cardiac sarcoidosis [25] | |
- Exudative type: marked lymphocytic infiltration, diffuse edema, collection of histiocytes in the interstitium | |
- Granuloma type: typical epithelioid-cell-granuloma formation with giant cells and lymphocytes | |
- Combined type: some atrophic epithelioid-cell-granulomatous and fibrous change | |
- Fibrotic type: the myocardial tissue replaced by fibro-hyaline changes, with sparse lymphocytic infiltration. | |
3. Phases of the lesion in cardiac sarcoidosis [36] | |
- Early (primarily lymphocytic) phase: areas indistinguishable from lymphocytic myocarditis | |
- Intermediate (primarily granulomatous) phase: active granulomatous lesion | |
- Late (primarily scar) phase: areas composed predominantly of scar |